This Open Access edition of the European Society for Blood and Marrow Transplantation (EBMT) handbook addresses the latest developments and innovations in hematopoietic stem cell transplantation and cellular therapy. Consisting of 93 chapters, it has been written by 175 leading experts in the field. Discussing all types of stem cell and bone marrow transplantation, including haplo-identical stem cell and cord blood transplantation, it also covers the indications for transplantation, the management of early and late complications as well as the new and rapidly evolving field of cellular therapies. This book provides an unparalleled description of current practices to enhance readers' knowledge and practice skills.

Text in French.

This issue of Hematology/Oncology Clinics, guest edited by Andrew A. Lane, will cover Blastic Plasmacytoid Dendritic Cell Neoplasm. This issue is one of six selected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz. Topics discussed in this issue include: Clinical Presentation and Pathology, Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm: DNA mutations and epigenetics, Cytogenetics of Blastic Plasmacytoid Dendritic Cell Neoplasm, Blastic Plasmacytoid Dendritic Cell Neoplasm Chemotherapy, CD123 and Leukemia Stem Cells, Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm, Immune Therapies Targeting CD123 in Blastic Plasmacytoid Dendritic Cell Neoplasm, Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm, Blastic Plasmacytoid Dendritic Cell Neoplasm in Children, European Perspective, Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm, and Social Media in Blastic Plasmacytoid Dendritic Cell Neoplasm and Other Rare Diseases.

This issue of Hematology/Oncology Clinics, guest edited by David P. Steensma, will cover key topics in Myelodysplastic Syndromes. This issue is one of six selected each year by our series consulting editors, George P. Canellos and Edward J. Benz. Topics discussed in this issue will include: Novel prognostic models for MDS, Evaluating MDS patients with genetic mutations that might be germline, Implications of splicing mutations in MDS for pathophysiology and therapy, Assessing quality of life in MDS/MPN overlap patients, Creation of a clinic for patients with clonal hematopoiesis, Luspatercept in MDS, Prospects for venetoclax in MDS, Treatment of acquired sideroblastic anemias, Treatment of patients with AML arising from MDS, Targeting TP53 mutations in MDS, among others.